Nuvectis Pharma, Inc. NVCT 深 滬
已收盤 08-01 16:00:00 美东时间
6.80
-0.160
-2.30%
華盛通- 最 高6.95
- 今 開6.91
- 成交量 9.94万股
- 最 低 6.75
- 昨 收 6.96
- 總市值 1.61亿
- 52周最高 11.80
- 市盈率 靜 --
- 換手率 0.42%
- 52周最低 4.44
- 委 比 -76.26%
- 總股本 2363.46万
- 歷史最高 20.92
- 量 比 0.58
- 振 幅 2.87%
- 歷史最低 3.08
- 每 手 1
- 風險率 1.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) stock rose 62.6% to $8.78 during Thurs...
07-31 20:08
Nuvectis Pharma Shared Final Clinical Data Update From The Phase 1b Study Of NXP800 In Recurrent, Platinum Resistant, ARID1a-mutated Ovarian Cancer And Reported On The Progress Towards The Initiation Of The Phase 1b Program For NXP900
As part of the NXP800 Phase 1b study, 17 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer were treated with NXP800 at the target dose of 75 mg/day, administered intermittently or daily, with
07-31 19:48
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Nuvectis Pharma provided updates on NXP800 and NXP900. NXP800 showed partial responses and stable disease in ovarian cancer, with thrombocytopenia managed via intermittent dosing. The company is evaluating its potential in other cancers. NXP900 completed successful DDI and Phase 1a studies, with plans for Phase 1b initiation soon. The company prioritizes advancing NXP900 while exploring NXP800 opportunities elsewhere.
07-31 11:45
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
Nuvectis Pharma announced successful completion of a DDI study for NXP900, a weak CYP3A inhibitor, supporting its potential as a combination partner with EGFR/ALK inhibitors for NSCLC. The study in 14 healthy volunteers showed NXP900 increased Midazolam levels by <2-fold, with no serious adverse events reported. This data supports advancing NXP900 into Phase 1b trials, targeting cancers sensitive to SRC/YES1 inhibition, leveraging its unique mech...
07-08 12:00
Nuvectis Pharma Approves Proposals at Annual Meeting
Nuvectis Pharma ( ($NVCT) ) just unveiled an update. On June 12, 2025, Nuvectis...
06-14 05:37
Nuvectis Pharma Launches New $60M Stock Offering Program
Nuvectis Pharma ( ($NVCT) ) has issued an announcement. On May 9, 2025, Nuvecti...
05-10 05:51
Nuvectis Pharma GAAP EPS of $0.27
Nuvectis Pharma press release (NASDAQ:NVCT): GAAP EPS of $0.27. Cash and cash equivalents were $29.9 million as of March 31, 2025, compared to $18.5 million as of December 31, 2024. More on Nuvectis P...
05-06 23:18
美股大行评级 | 潜在涨幅117.92%！Proficient Auto Logistics获Stifel升目标价至18美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114836103639961600.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Stifel：维持Proficient Auto Logistics(PAL)"买入"评级，目标价从17美元升至18美元</p> <p>• Craig-Hallum：上调Sportsman's Warehouse(SPWH
04-04 15:42
美股大行评级 | 花旗：维持爱科集团"中性"评级，目标价从95美元升至98美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1108674722736648193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从18美元升至19美元</p> <p>• Ascendiant Capital：维持Daxor Corp.(DXR)"买入"评级，目标
03-18 10:15
